Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma. [electronic resource]
Producer: 20020703Description: 836-45 p. digitalISSN:- 1078-0432
- Antibodies, Monoclonal -- pharmacology
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Combined Chemotherapy Protocols
- Apoptosis -- drug effects
- Apoptotic Protease-Activating Factor 1
- Blotting, Western
- CASP8 and FADD-Like Apoptosis Regulating Protein
- Carrier Proteins
- Caspase Inhibitors
- Caspases -- metabolism
- Cisplatin -- pharmacology
- Combined Modality Therapy
- Cytochrome c Group -- metabolism
- Dose-Response Relationship, Drug
- Drug Resistance, Neoplasm
- Enzyme Activation -- drug effects
- Enzyme Inhibitors -- pharmacology
- Fas Ligand Protein
- Humans
- Intracellular Signaling Peptides and Proteins
- Lymphoma, AIDS-Related -- metabolism
- Membrane Glycoproteins -- metabolism
- Mitochondria -- drug effects
- Proteins -- metabolism
- Proto-Oncogene Proteins c-bcl-2 -- metabolism
- Reactive Oxygen Species -- metabolism
- Reverse Transcriptase Polymerase Chain Reaction
- Rituximab
- Signal Transduction -- drug effects
- Tumor Cells, Cultured -- drug effects
- fas Receptor -- metabolism
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.